| Summary: | 碩士 === 國立臺灣大學 === 護理學研究所 === 97 === Targeted therapy is one of treatment for tumor. The side effect of EGFR inhibitors is the manifestation of skin toxicities and may influence patients’ quality of life. Limited studies have explored these problems. The purposes of this study were to examine (1) patients’ experiences related to dermatologic toxicities; and its impact on quality of life and body image; and (2) patients’ strategies used to cope with side effects related to targeted therapy. A cross-sectional study with purposive sampling was used. Data were collected by (1) Symptom Severity Scale（NCI CTC v3.0---dermatology/skin; (2) skin related quality of life（Skindex-29）, Hospital Anxiety and Depression Scale (HADS), Body image scale （BIS）and Coping strategies scale. A total of 94 lung cancer patients were recruited from a medical center in Taipei. The results showed that 91.5% of patients had dermotologic toxicities and 70.2% of patients had multi-locational skin change. Incidences of these side effects as their descending order were (1) skin rash, (2) pruritus, and (3) dry skin. The severity of these symptoms as their ranking order was (1) pruritus, (2) dry skin, and (3) skin rash. The most frequently used coping strategies were (1) using prescription by doctor, (2) using the lotion, (3) using antiseptic before nail change. Pruritus was the most significant side effect to affect patients’ life. There were significant correlations among NIC CTC v3---dermatology/skin skindex-29. ECOGE PS and depression. Tarceva is significantly presented more severe side effects than Iressa. To whom received EGFR-TKI less than three months had more negative body image about themselves. Longitudinal studies would be necessary to further examine the changes of dermotologic toxicity and quality of life, and body image change in lung cancer patients.
|
|---|
